Semaglutide vs Tirzepatide vs Retatrutide: GLP-1 Peptide Comparison Guide

——–|————-|————-|————-|

GLP-1 receptor ✓ Strong ✓ Strong ✓ Strong GIP receptor ✗ ✓ Strong ✓ Moderate Glucagon receptor ✗ ✗ ✓ Moderate Insulin secretion ✓ ✓✓ ✓✓ Appetite suppression ✓✓ ✓✓ ✓✓✓ Gastric emptying ✓✓ ✓ ✓ Energy expenditure ✗ ✗ ✓✓ Fat oxidation ✗ ✓ ✓✓ Liver fat reduction ✓ ✓✓ ✓✓✓

Efficacy and Weight Loss Comparison

Clinical Trial Weight Loss Data

Compound Trial Dose Weight Loss (% body weight) Duration Semaglutide STEP 1 2.4mg weekly -14.9% 68 weeks Semaglutide STEP 5 2.4mg weekly -15.2% 104 weeks Tirzepatide SURMOUNT-1 5mg weekly -15.0% 72 weeks Tirzepatide SURMOUNT-1 10mg weekly -19.5% 72 weeks Tirzepatide SURMOUNT-1 15mg weekly -20.9% 72 weeks Retatrutide Phase 2 1mg weekly -8.7% 24 weeks Retatrutide Phase 2 4mg weekly -17.1% 24 weeks Retatrutide Phase 2 8mg weekly -22.8% 24 weeks Retatrutide Phase 2 12mg weekly -24.2% 24 weeks

Key Efficacy Observations

Dose-response relationship: All three show increasing weight loss with higher doses

Generation effect: Tirzepatide > Semaglutide; Retatrutide > Tirzepatide at comparable stages

Time to maximum effect: Semaglutide plateaus at ~12-18 months; Tirzepatide at ~18 months; Retatrutide still showing decline at 24 weeks

Completer analysis: Weight loss is even greater in those who complete trials (Retatrutide up to -26%+)

Metabolic improvements: All improve glucose, lipids, blood pressure — Retatrutide shows greatest liver fat reduction

Glycemic Control (HbA1c Reduction)

Compound Dose HbA1c Reduction Semaglutide 1.0mg weekly -1.5% to -1.8% Tirzepatide 15mg weekly -2.0% to -2.4% Retatrutide 8-12mg weekly -2.0% to -2.5% (estimated)

Dosage and Administration Comparison

Semaglutide Research Dosage

Phase Dose Frequency Duration Starting 0.25mg Weekly 4 weeks Titration 1 0.5mg Weekly 4 weeks Titration 2 1.0mg Weekly 4 weeks Maintenance (diabetes) 1.0-2.0mg Weekly Ongoing Maintenance (weight) 2.4mg Weekly Ongoing Research max 2.4mg Weekly As needed

Tirzepatide Research Dosage

Phase Dose Frequency Duration Starting 2.5mg Weekly 4 weeks Titration 1 5.0mg Weekly 4 weeks Titration 2 7.5mg Weekly 4 weeks Titration 3 10mg Weekly 4 weeks Maintenance (diabetes) 5-15mg Weekly Ongoing Maintenance (weight) 10-15mg Weekly Ongoing Research max 15mg Weekly As needed

Retatrutide Research Dosage

Phase Dose Frequency Duration Starting 0.5mg Weekly 4 weeks Titration 1 1mg Weekly 4 weeks Titration 2 2mg Weekly 4 weeks Titration 3 4mg Weekly 4 weeks Titration 4 6mg Weekly 4 weeks Titration 5 8mg Weekly 4 weeks Maintenance (research) 4-12mg Weekly Ongoing Research max 12mg Weekly As needed

Reconstitution Guide for All Three

All three peptides are reconstituted similarly:

Sanitize vial stopper with alcohol

Add bacteriostatic water:

– Semaglutide 5mg + 2mL = 2.5mg/mL
– Tirzepatide 10mg + 2mL = 5mg/mL
– Retatrutide 10mg + 2mL = 5mg/mL

Swirl gently until dissolved

Store in refrigerator at 2-8°C

Use within 30 days

Note: Some semaglutide formulations may require specific reconstitution protocols. Always follow peptide-specific guidelines.

Use our Peptide Reconstitution Calculator for precise dosing.

Side Effects Comparison

Common Side Effects (>10%)

Side Effect Semaglutide Tirzepatide Retatrutide Nausea 44% 34-45% 30-40% Diarrhea 30% 25-30% 25-35% Vomiting 24% 20-25% 15-25% Constipation 24% 15-20% 15-20% Abdominal pain 20% 15-20% 15-20% Headache 14% 10-15% 10-15% Fatigue 10% 10-15% 10-15%

Side Effect Severity and Tolerability

Semaglutide: High incidence of GI side effects, especially during titration; ~10-15% discontinue due to side effects

Tirzepatide: Slightly better GI tolerability than semaglutide at equivalent weight loss; GIP may mitigate some nausea; ~5-10% discontinue

Retatrutide: Side effect profile still being characterized; GI effects similar to tirzepatide; glucagon component may cause additional effects (increased heart rate, blood pressure changes); discontinuation rates similar to tirzepatide in early trials

Serious Adverse Events (Rare but Important)

Event Semaglutide Tirzepatide Retatrutide Pancreatitis Rare (0.3-0.5%) Rare (0.2-0.4%) Rare (being studied) Gallbladder disease Increased risk Increased risk Increased risk (expected) Hypoglycemia Low (with insulin) Low Low (glucagon may protect) Heart rate increase 2-4 bpm 2-4 bpm 4-8 bpm (glucagon effect) Blood pressure changes Slight decrease Slight decrease Variable (being studied) Thyroid C-cell tumors Theoretical (rodent studies) Theoretical Theoretical

Contraindications

All three are contraindicated in:

Personal or family history of medullary thyroid carcinoma (MTC)

Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Known hypersensitivity to the compound

Pregnancy and lactation

History of severe pancreatitis

Which Peptide to Choose for Research?

Choose Semaglutide If:

You need the most extensively studied and characterized compound

Research focuses specifically on GLP-1 receptor biology

Budget is a consideration (generally lower cost than newer compounds)

Study population has type 2 diabetes with cardiovascular risk

You require long-term safety data (8+ years of clinical use)

Research involves NASH or liver disease (semaglutide has NASH data)

Choose Tirzepatide If:

You want greater weight loss than GLP-1 monotherapy

Research focuses on dual GIP/GLP-1 receptor biology

Better GI tolerability is important for study retention

Study involves severe obesity or metabolic syndrome

You want a balance between efficacy and established safety

Research involves lipid metabolism and cardiovascular risk

Choose Retatrutide If:

You need maximum weight loss efficacy (24%+)

Research focuses on triple receptor agonism

Study involves severe obesity or treatment-resistant weight gain

You want to study energy expenditure and glucagon effects

Research involves liver fat and NAFLD/NASH

You are studying next-generation metabolic therapies

Note: Less long-term safety data available

Research Stacking Considerations

Some research protocols combine these peptides with other compounds:

GLP-1 + CJC-1295/Ipamorelin: Weight loss + growth hormone for muscle preservation

GLP-1 + BPC-157: Weight loss + gut protection (may mitigate GI side effects)

GLP-1 + NAD+: Metabolic health + cellular energy

GLP-1 + L-Carnitine: Enhanced fat oxidation

Important: Combination research should only be conducted in controlled settings with proper monitoring.

Purity and Quality Considerations

When sourcing these peptides for research:

HPLC purity: ≥98% (target >99%)

Mass spectrometry: Confirms correct molecular weight and sequence

Endotoxin testing: Essential for in vivo research

CoA documentation: Certificate of Analysis with batch-specific testing

Storage: Lyophilized powder at -20°C; reconstituted at 2-8°C

Manufacturing: GMP-compliant facilities preferred

Quality note: These are complex peptides with specific amino acid sequences and modifications. Low-quality or impure product can produce unreliable research results. Always verify purity and identity.

Hanpro Peptides provides third-party tested Semaglutide, Tirzepatide, and Retatrutide with full CoA documentation.

Related Weight Management Peptides

Explore these additional metabolic research compounds:

Mazdutide — Another dual GIP/GLP-1 agonist (Chinese market)

Survodutide — Dual GLP-1/glucagon receptor agonist

Cagrilintide — Amylin receptor agonist (often combined with semaglutide)

AOD9604 — Growth hormone fragment for fat metabolism

5-Amino-1MQ — NNMT inhibitor for metabolic research

Tesofensine — Triple monoamine reuptake inhibitor for appetite

Frequently Asked Questions

Which is better for weight loss: Semaglutide, Tirzepatide, or Retatrutide?

Based on clinical trial data, Retatrutide produces the greatest weight loss (up to 24.2% at 24 weeks, with projections of 26%+ at 48 weeks), followed by Tirzepatide (up to 20.9% at 72 weeks), then Semaglutide (up to 15.2% at 104 weeks). However, “better” depends on research goals — semaglutide has the most safety data, while retatrutide is still investigational.

How do these peptides differ in mechanism?

Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GIP and GLP-1 receptors (dual agonist). Retatrutide activates GIP, GLP-1, and glucagon receptors (triple agonist). The additional receptors provide complementary metabolic effects — GIP enhances insulin and lipid metabolism, while glucagon increases energy expenditure and fat oxidation.

Are these peptides safe for research use?

All three have been studied in large clinical trials and are generally well-tolerated. Common side effects are gastrointestinal (nausea, diarrhea, vomiting) and are most prominent during dose titration. Serious adverse events (pancreatitis, gallbladder disease) are rare. However, retatrutide has less long-term safety data, and all three should only be used in controlled research settings with proper monitoring.

Can these peptides be used together or stacked?

Combining different GLP-1 class peptides is generally not recommended due to overlapping mechanisms and increased side effect risk. However, these peptides are sometimes studied in combination with other classes of compounds (e.g., CJC-1295 for growth hormone, BPC-157 for gut protection, NAD+ for cellular energy). Any combination research should be conducted with careful monitoring and appropriate ethical approval.

How long does it take to see weight loss results?

In research settings, initial weight loss typically begins within 2-4 weeks of starting treatment. Significant weight loss (5-10% body weight) is usually observed by 12-16 weeks. Maximum weight loss occurs at different timepoints: Semaglutide at ~12-18 months, Tirzepatide at ~18 months, and Retatrutide is still showing continued weight loss at 24 weeks in early trials. Consistent dosing and gradual titration are key to maximizing results while minimizing side effects.

---

*Disclaimer: This article is for educational and research informational purposes only. Semaglutide, Tirzepatide, and Retatrutide are discussed as research-use-only compounds. While some FDA-approved formulations exist for specific medical indications, the research-grade peptide forms discussed here are not approved for human consumption or treatment. All information is based on published clinical trials and preclinical research and does not constitute medical advice.*